UCB China growth - soaring into a new era

More than 1,000 colleagues joined UCB China’s ‘Soaring into the New Era’ annual kick off meeting in February, with a focus on how to create more value for patients in China.

Veronique Toully (Managing Director China) thanked all of UCB colleagues in China for their dedication in 2014 and Mark McDade (Executive VP Patient Value Operations) outlined what UCB’s ‘new era’ means to China. Colleagues discussed the latest advances of CVNK in China. The latest good news from Neupro? which had positive top-line results from two Phase 3 studies for treating patients with early- and advanced-stage idiopathic Parkinson’s disease. UCB intends to submit a regulatory application in China for Neupro? this year. Meanwhile Keppra? will launch the IV (intravenous) solution in China late this year and is expected to serve 214,000 patients in China in 2015.

Colleagues at the meeting also talked about UCB’s future pipeline and development in China, which is strong.

For the first time at their kick-off meeting, UCB China organized a ‘Patient Value Table’ which was attended by health care professionals (doctors, community health care providers and nurses) and economists with stimulating discussions on how to create value for patients.